Navigation Links
Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013
Date:5/28/2009

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe, according to Millennium Research Group

WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased competitor focus, and the release of new drug-eluting devices for these indications. Combined, these factors will drive the markets for lower extremity PV stents and percutaneous transluminal angioplasty (PTA) balloon catheters to reach combined revenues in excess of $180 million by 2013.

The number of endovascular femoropopliteal (fem-pop) procedures performed in Europe is experiencing double-digit year-over-year growth, driven primarily by positive data released from clinical trials such as Cordis' SIROCCO and Edwards Lifesciences' RESILIENT. The positive results from these trials have demonstrated both promising patency rates and reduced stent fracture rates, which will continue to bolster physician confidence in fem-pop stenting. Fem-pop PTA procedure volumes in Europe will grow in tandem with fem-pop stenting, which often involves predilation of the lesion or postdilation of the stent using PTA balloon catheters. As a result, most major PV stent manufacturers are now focusing on the fem-pop indication for technology development and marketing.

"Endovascular infrapopliteal procedures, which treat below-the-knee peripheral artery disease, are also growing rapidly," says Stephanie Labelle, Senior Analyst at MRG. "Although revenues in both the PV stent and PTA balloon catheter markets were relatively small for the infrapopliteal indication in 2008, infrapopliteal procedures will continue to outgrow other PV stenting indications through 2013. In addition, the introduction of drug-eluting stents and balloons indicated for infrapopliteal procedures will generate a considerable amount of physician excitement, which will help to boost market revenues over the years to come."

MRG's European Markets for Peripheral Vascular Devices 2009 report provides coverage of key industry competitors, including Abbott Vascular, Boston Scientific, Cook Medical, Cordis, C. R. Bard, Medtronic Vascular, Terumo Medical, W. L. Gore, and many more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources, Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
2. AHRQ-Funded Study Finds Lower Risk of Death and Heart Attack in Patients With Drug-Coated Stent Implants Compared to Those With Bare Metal Stents
3. New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
4. Experience Not Always the Best Prescription for Snowblowers
5. Statins Lower Stroke Severity, Improve Recovery
6. Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet
7. AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
8. Implantable Defibrillators Lower Risk of Death in Older Heart Patients
9. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Want a Reason to Love Your Lower Belly Fat? Its Rich in Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):